Evidence map›Paper›PMID 38811223›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Chronic Hepatitis B in Which HBs Antigen Seroclearance Was Induced by Pegpegylated-interferonα-2a after Hepatocellular Carcinoma Treatment with Nucleos(t)ide Analogues: A Five-year Follow-up.

Shima Mimura, Masafumi Ono, Koji Fujita, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Joji Tani, Asahiro Morishita, Seiko Kagawa and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shima MimuraDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Masafumi OnoDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Koji FujitaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Kei TakumaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Mai NakaharaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Kyoko OuraDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Tomoko TadokoroDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Joji TaniDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Asahiro MorishitaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.
Seiko KagawaDepartment of Pathology, Faculty of Medicine, Kagawa University, Japan.
Keiichi OkanoDepartment of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Japan.
Takashi HimotoDepartment of Medical Technology, Kagawa Prefectural University of Health Sciences, Japan.
Tsutomu MasakiDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report a 40-year-old Japanese man with chronic hepatitis B genotype C (viral load 6.7 Log copies/mL) who developed hepatocellular carcinoma (HCC) despite achieving undetectable hepatitis B virus (HBV)-DNA levels with nucleos(t)ide analog (NA) treatment (entecavir). Notably, his hepatitis B surface antigen (HBsAg) level remained elevated at 388.4 IU/mL. Given the continued risk of carcinogenesis associated with HBsAg positivity, we initiated pegylated interferon (PEG-IFN) therapy one month after HCC surgery. Following three periods of PEG-IFN treatment, HBsAg seroclearance (HBsAg-negative state) was achieved.

Indexed as

Antiviral AgentsCarcinoma, HepatocellularHepatitis B, ChronicHepatitis B Surface AntigensInterferon-alphaLiver NeoplasmsPolyethylene GlycolsAdultFollow-Up StudiesGuanineHumansMaleRecombinant ProteinsAntiviral AgentsentecavirGuanineHepatitis B Surface AntigensInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant Proteinschronic hepatitis Bhepatitis B surface antigenhepatocellular carcinomanucleos(t)ide analoguepegylated interferon

Identifiers

PMID38811223
PMCPMC11802215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.